Steric disruption of EGFR oligomerization overcomes therapy resistance in non-small cell lung cancer

Area of Science:

• Molecular biology
• Cancer research
• Drug discovery

Background:

• Acquired drug resistance mutations in epidermal growth factor receptor (EGFR) are a major challenge in non-small cell lung cancer (NSCLC) treatment.
• EGFR oligomerization is known to modulate receptor signaling, but its role in resistance mutations is not well understood.

Purpose of the Study:

• To investigate the real-time relationship between the oligomerization of oncogenic and resistant EGFR mutants and their downstream signaling.
• To explore strategies for overcoming EGFR-mediated drug resistance in NSCLC.

Main Methods:

• Utilized a fluorescent protein-based proximity probe and signaling reporter in living cells to monitor EGFR oligomerization and signaling in real-time.
• Assessed the correlation between EGFR oligomerization levels and the efficacy of tyrosine kinase inhibitors (TKIs) and allosteric drugs.
• Investigated the effect of sterically disrupting EGFR oligomerization using genetic fusion of bulky proteins and extracellular EGFR binders.

Main Results:

• EGFR mutants resistant to TKIs displayed higher oligomerization levels compared to wild-type EGFR.
• The efficacy of TKIs and allosteric drugs was inversely proportional to the degree of EGFR receptor oligomerization.
• Steric disruption of EGFR oligomerization, through genetic fusion or extracellular binders, effectively overcame resistance and suppressed cancer cell proliferation.

Conclusions:

• Steric disruption of EGFR oligomerization represents a promising therapeutic strategy to overcome drug resistance in NSCLC.
• The study introduces a novel screening platform for the development of competitive and allosteric inhibitors targeting EGFR.